Published in Health Insurance Week, July 2nd, 2006
Study 1: Researchers outline the transmissibility, infectivity, and immunogenicity of a live human parainfluenza type 3 virus vaccine (HP1V3cp45) among susceptible infants and toddlers in a recent issue of Vaccine.
"This study examined the transmissibility between young children of an intranasally administered live attenuated human parainfluenza virus type 3 (HPIV3)-cp45 vaccine candidate. Eighty subjects were enrolled in playgroups among whom there was at least one infected vaccinee in close contact with a seronegative placebo recipient over 21 days without a...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Insurance Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.